Investigation into Omeros Corporation Securities Fraud
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 53 minutes ago
0mins
Source: PRnewswire
- Securities Fraud Investigation: Pomerantz LLP is investigating Omeros Corporation for potential securities fraud and other unlawful business practices, which could impact the company's reputation and shareholder confidence.
- Negative Regulatory Opinion: On June 26, 2026, Omeros announced that the CHMP of the EMA issued a negative opinion on its marketing authorization application for narsoplimab for TA-TMA treatment, potentially limiting future sales.
- Significant Stock Price Drop: Following the negative news, Omeros's stock price fell by $2.05, or 19.12%, closing at $8.67 per share, reflecting market pessimism regarding the company's outlook.
- Potential Legal Action: Pomerantz LLP advises investors to join the class action, indicating that the company faces legal risks that could lead to further financial losses and reputational damage.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OMER?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OMER
Wall Street analysts forecast OMER stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 10.330
Low
36.00
Averages
43.67
High
55.00
Current: 10.330
Low
36.00
Averages
43.67
High
55.00
About OMER
Omeros Corporation is a clinical-stage biopharmaceutical company. The Company focuses on discovering, developing, and commercializing first-in-class small-molecule and protein therapeutics for both large-market and orphan indications, with a particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. Its clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program. Its commercial product, YARTEMLEA, is the approved inhibitor of the lectin pathway of complement. YARTEMLEA is used for the treatment of TA-TMA in adults and in children ages two years and older. YARTEMLEA selectively inhibits MASP-2, blocking pathway activation while preserving classical and alternative complement pathway functions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investment Choice Between Heartflow and Omeros in 2026
- Revenue Growth Comparison: Heartflow achieved approximately $176 million in revenue for FY 2025, a 40% increase year-over-year, despite a net loss of $116.8 million, indicating strong market demand for its core FFR CT analysis product; however, its heavy reliance on a single product poses significant risks.
- Omeros Commercialization Progress: Following the approval of Yartemlea at the end of 2025, Omeros did not book any revenue that year but expects $9.89 million in sales for Q1 2026, reflecting strong market interest in the treatment, with management anticipating significant revenue growth in the future.
- Cash Flow Status: Heartflow reported nearly negative $59 million in free cash flow for 2025, highlighting the high costs associated with its technology commercialization, while Omeros faced a negative $116.2 million in free cash flow, indicating financial pressure in drug development and marketing.
- Market Outlook Analysis: While Heartflow's application of AI technology is promising, Omeros's transition to a commercial entity and its partnership with Novo Nordisk may provide more stable revenue streams, with analysts projecting profitability for Omeros by 2028, suggesting its long-term investment value.
See More
Comparing Investment Prospects of Heartflow and Omeros
- Heartflow Revenue Growth: In FY 2025, Heartflow reported approximately $176 million in revenue, a 40% increase year-over-year, despite a net loss of $116.8 million, highlighting its heavy reliance on the core FFR CT Analysis product and the need to monitor potential policy impacts on revenue.
- Omeros Commercial Transition: Omeros launched its first commercial product, Yartemlea, at the end of 2025, and although it did not generate revenue that year, it achieved $9.89 million in sales in Q1 2026, indicating strong market interest and potential for profitability in the future.
- Market Competition Risks: Heartflow faces significant risks from government policy changes that could reduce reimbursements for its core product by 15%, along with ongoing intellectual property litigation that may affect investor sentiment, necessitating careful evaluation of its market position.
- Omeros Dependency: Omeros is highly dependent on the commercial success of Yartemlea and its partnership with Novo Nordisk, making any setbacks in the product launch potentially devastating to its stock, while the company continues to rely on capital markets to sustain operations.
See More
Omeros Corporation Under Investigation for Securities Law Violations
- Investigation Launched: The Schall Law Firm has announced an investigation into Omeros Corporation, focusing on whether the company issued false or misleading statements or failed to disclose information critical to investors, potentially harming shareholder rights.
- Negative Opinion: Omeros issued a press release on June 26, 2026, updating the status of its marketing authorization application (MAA) for narsoplimab for TA-TMA, revealing that the CHMP has adopted a negative opinion, which adversely affects the company's market outlook.
- Stock Price Plunge: Following the CHMP's negative opinion, Omeros's shares fell by more than 19.1% on the same day, indicating a strong market reaction to the news that could lead to diminished investor confidence.
- Investor Rights: The Schall Law Firm encourages affected investors to reach out to discuss their legal rights, highlighting the firm's focus on securities class action lawsuits and shareholder rights litigation, which may provide legal support for investors.
See More
Omeros Corporation Faces Securities Fraud Investigation
- Securities Fraud Investigation: Pomerantz LLP is investigating Omeros Corporation for potential securities fraud and other unlawful business practices, advising investors to contact them, which could lead to legal liabilities and financial repercussions for the company.
- Negative Regulatory Opinion: On June 26, 2026, Omeros announced that the CHMP of the European Medicines Agency issued a negative opinion on its marketing authorization application for narsoplimab to treat TA-TMA, impacting the product's market entry and future revenue potential.
- Significant Stock Decline: Following the negative news, Omeros's stock price fell by $2.05, or 19.12%, closing at $8.67 per share, which may undermine investor confidence and exacerbate market volatility.
- Potential Legal Consequences: The investigation by Pomerantz LLP could lead to the formation of a class action lawsuit, and if Omeros and its executives are found to have engaged in misconduct, it could have long-term implications for the company's reputation and financial health.
See More
High Options Trading Volume for Qualcomm and Replimune
- Qualcomm Options Volume: Qualcomm (QCOM) saw an options trading volume of 126,866 contracts today, representing approximately 12.7 million shares, which is about 57.5% of its average daily trading volume of 22 million shares over the past month, indicating strong market interest in its future performance.
- Bullish Call Options: Notably, the $200 strike call option expiring on June 26, 2026, has seen 6,196 contracts traded today, representing around 619,600 underlying shares, suggesting that investors are increasingly optimistic about Qualcomm's stock price appreciation.
- Replimune Options Activity: Replimune (REPL) has recorded an options trading volume of 35,327 contracts today, equivalent to approximately 3.5 million shares, which accounts for about 56.1% of its average daily trading volume of 6.3 million shares over the past month, reflecting investor confidence in its growth potential.
- Call Options Interest: Particularly, the $15 strike call option expiring on August 21, 2026, has seen a trading volume of 5,896 contracts today, representing approximately 589,600 shares, indicating a bullish sentiment among market participants regarding Replimune's stock price trajectory.
See More
Omeros Shares Drop 25% After EU Panel Rejects Narsoplimab Therapy
- Therapy Rejection: Omeros's transplant therapy narsoplimab was not endorsed by an expert panel of the EU drug regulator, leading to a ~25% drop in the company's shares during premarket trading.
- Negative Opinion Issued: The European Medicines Agency's Committee for Medicinal Products for Human Use adopted a negative opinion on the marketing authorization application for narsoplimab, impacting its approval process in Europe.
- Current U.S. Market Status: The therapy is already marketed in the U.S. under the brand name Yartemlea for treating thrombotic microangiopathy associated with hematopoietic stem cell transplants, indicating potential in the U.S. market.
- Future Plans: Omeros plans to request a review from an ad hoc expert group regarding the decision, with the CEO expressing confidence that Yartemlea deserves approval in Europe, and expects to achieve positive cash flow within 18 months as early uptake builds.
See More
Investment Choice Between Heartflow and Omeros in 2026
- Revenue Growth Comparison: Heartflow achieved approximately $176 million in revenue for FY 2025, a 40% increase year-over-year, despite a net loss of $116.8 million, indicating strong market demand for its core FFR CT analysis product; however, its heavy reliance on a single product poses significant risks.
- Omeros Commercialization Progress: Following the approval of Yartemlea at the end of 2025, Omeros did not book any revenue that year but expects $9.89 million in sales for Q1 2026, reflecting strong market interest in the treatment, with management anticipating significant revenue growth in the future.
- Cash Flow Status: Heartflow reported nearly negative $59 million in free cash flow for 2025, highlighting the high costs associated with its technology commercialization, while Omeros faced a negative $116.2 million in free cash flow, indicating financial pressure in drug development and marketing.
- Market Outlook Analysis: While Heartflow's application of AI technology is promising, Omeros's transition to a commercial entity and its partnership with Novo Nordisk may provide more stable revenue streams, with analysts projecting profitability for Omeros by 2028, suggesting its long-term investment value.
See More
Comparing Investment Prospects of Heartflow and Omeros
- Heartflow Revenue Growth: In FY 2025, Heartflow reported approximately $176 million in revenue, a 40% increase year-over-year, despite a net loss of $116.8 million, highlighting its heavy reliance on the core FFR CT Analysis product and the need to monitor potential policy impacts on revenue.
- Omeros Commercial Transition: Omeros launched its first commercial product, Yartemlea, at the end of 2025, and although it did not generate revenue that year, it achieved $9.89 million in sales in Q1 2026, indicating strong market interest and potential for profitability in the future.
- Market Competition Risks: Heartflow faces significant risks from government policy changes that could reduce reimbursements for its core product by 15%, along with ongoing intellectual property litigation that may affect investor sentiment, necessitating careful evaluation of its market position.
- Omeros Dependency: Omeros is highly dependent on the commercial success of Yartemlea and its partnership with Novo Nordisk, making any setbacks in the product launch potentially devastating to its stock, while the company continues to rely on capital markets to sustain operations.
See More
Omeros Corporation Under Investigation for Securities Law Violations
- Investigation Launched: The Schall Law Firm has announced an investigation into Omeros Corporation, focusing on whether the company issued false or misleading statements or failed to disclose information critical to investors, potentially harming shareholder rights.
- Negative Opinion: Omeros issued a press release on June 26, 2026, updating the status of its marketing authorization application (MAA) for narsoplimab for TA-TMA, revealing that the CHMP has adopted a negative opinion, which adversely affects the company's market outlook.
- Stock Price Plunge: Following the CHMP's negative opinion, Omeros's shares fell by more than 19.1% on the same day, indicating a strong market reaction to the news that could lead to diminished investor confidence.
- Investor Rights: The Schall Law Firm encourages affected investors to reach out to discuss their legal rights, highlighting the firm's focus on securities class action lawsuits and shareholder rights litigation, which may provide legal support for investors.
See More
Omeros Corporation Faces Securities Fraud Investigation
- Securities Fraud Investigation: Pomerantz LLP is investigating Omeros Corporation for potential securities fraud and other unlawful business practices, advising investors to contact them, which could lead to legal liabilities and financial repercussions for the company.
- Negative Regulatory Opinion: On June 26, 2026, Omeros announced that the CHMP of the European Medicines Agency issued a negative opinion on its marketing authorization application for narsoplimab to treat TA-TMA, impacting the product's market entry and future revenue potential.
- Significant Stock Decline: Following the negative news, Omeros's stock price fell by $2.05, or 19.12%, closing at $8.67 per share, which may undermine investor confidence and exacerbate market volatility.
- Potential Legal Consequences: The investigation by Pomerantz LLP could lead to the formation of a class action lawsuit, and if Omeros and its executives are found to have engaged in misconduct, it could have long-term implications for the company's reputation and financial health.
See More
High Options Trading Volume for Qualcomm and Replimune
- Qualcomm Options Volume: Qualcomm (QCOM) saw an options trading volume of 126,866 contracts today, representing approximately 12.7 million shares, which is about 57.5% of its average daily trading volume of 22 million shares over the past month, indicating strong market interest in its future performance.
- Bullish Call Options: Notably, the $200 strike call option expiring on June 26, 2026, has seen 6,196 contracts traded today, representing around 619,600 underlying shares, suggesting that investors are increasingly optimistic about Qualcomm's stock price appreciation.
- Replimune Options Activity: Replimune (REPL) has recorded an options trading volume of 35,327 contracts today, equivalent to approximately 3.5 million shares, which accounts for about 56.1% of its average daily trading volume of 6.3 million shares over the past month, reflecting investor confidence in its growth potential.
- Call Options Interest: Particularly, the $15 strike call option expiring on August 21, 2026, has seen a trading volume of 5,896 contracts today, representing approximately 589,600 shares, indicating a bullish sentiment among market participants regarding Replimune's stock price trajectory.
See More
Omeros Shares Drop 25% After EU Panel Rejects Narsoplimab Therapy
- Therapy Rejection: Omeros's transplant therapy narsoplimab was not endorsed by an expert panel of the EU drug regulator, leading to a ~25% drop in the company's shares during premarket trading.
- Negative Opinion Issued: The European Medicines Agency's Committee for Medicinal Products for Human Use adopted a negative opinion on the marketing authorization application for narsoplimab, impacting its approval process in Europe.
- Current U.S. Market Status: The therapy is already marketed in the U.S. under the brand name Yartemlea for treating thrombotic microangiopathy associated with hematopoietic stem cell transplants, indicating potential in the U.S. market.
- Future Plans: Omeros plans to request a review from an ad hoc expert group regarding the decision, with the CEO expressing confidence that Yartemlea deserves approval in Europe, and expects to achieve positive cash flow within 18 months as early uptake builds.
See More
